Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
BryoLogyx Inc
CHS Pharma Inc
Syptogenix Inc
VM Discovery Inc
Young Therapeutics LLC
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PKC Epsilon for Pervasive Developmental Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRKCE for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCE for HIV and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulindac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
Protein Kise C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Jul 26, 2021: Syptogenix discloses positive results of further Bryostatin trial alyses in presentation at Alzheimer’s Association Intertiol Conference 2021
Jul 14, 2021: Syptogenix to present data at Alzheimer’s Association Intertiol Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
Jul 07, 2021: Syptogenix announces regenerative patent award to treat Alzheimer’s disease
Jun 09, 2021: Syptogenix announces phase 2b NIH sponsored Alzheimer’s disease trial update
Apr 01, 2021: Syptogenix announces phase 2b Bryostatin-1 clinical trial update
Feb 04, 2021: Synthetic bryostatin available to expand neurodegenerative indication trials
Oct 13, 2020: BryoLogyx announces completion of world’s first GMP synthesis of bryostatin-1
Oct 07, 2020: Neurotrope begins Phase II trial of Alzheimer’s drug candidate
Aug 04, 2020: BryoLogyx announces cooperative research and development agreement for Bryostatin-1 with tiol Cancer Institute
Jul 30, 2020: Neurotrope Bioscience announces agreement with worldwide clinical trials, to conduct ongoing phase 2 study of Bryostatin-1, partially funded by NIH, for Alzheimer’s Disease
Jun 10, 2020: Neurotrope announces strategic partnership with BryoLogyx for supply of synthetic Bryostatin-1 and continuation of the tiol Cancer Institute (NCI) trial for childhood leukemia
May 28, 2020: Neurotrope launches new long-term clinical trial of Bryostatin with the tiol Institutes of Health for the treatment of patients with Alzheimer’s Disease
Jan 22, 2020: Neurotrope provides corporate update after completing Bryostatin-1 data alysis for advanced Alzheimer’s disease trial
Sep 10, 2019: Neurotrope Alzheimer’s Phase II trial fails to meet endpoints
Aug 13, 2019: Neurotrope announces publication highlighting the potential of bryostatin as a unique neurorestorative therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by BryoLogyx Inc, 2021
Pipeline by CHS Pharma Inc, 2021
Pipeline by Synaptogenix Inc, 2021
Pipeline by VM Discovery Inc, 2021
Pipeline by Young Therapeutics LLC, 2021
Dormant Projects, 2021
Discontinued Products, 2021